Home/Healthcare/Rare Diseases/Acute Myeloid Leukemia Market

Acute Myeloid Leukemia Market - Strategic Insights and Forecasts (2026-2031)

Market Size, Share, Forecasts and Trends Analysis By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Stem Cell Transplantation, Combination Therapy), By Drug Class (FLT3 Inhibitors, IDH Inhibitors, BCL-2 Inhibitors, Hypomethylating Agents, Antibody-Drug Conjugates, Conventional Chemotherapy Agents), By Disease Type (Newly Diagnosed AML, Relapsed/Refractory AML, Secondary AML, Therapy-Related AML), By Route of Administration (Oral, Intravenous, Subcutaneous), By End User (Hospitals, Specialty Cancer Centers, Academic and Research Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies), and Geography

$3,950
Single User License
Access Full Insights
Report OverviewSegmentationTable of ContentsCustomize Report

Request Customization

Tell us your specific requirements and we will customize this report for you.

📞

Your data is secure. We do not share information with any third party.

Acute Myeloid Leukemia Market Report

Report IDKSI-008703
PublishedMay 2026
Pages154
FormatPDF, Excel, PPT, Dashboard

Need Assistance?

Our research team is available to answer your questions.

Contact Us
Frequently Asked Questions

The AML market is projected to grow at a CAGR of 10.50%, reaching USD 38.22 billion by 2031 from USD 23.20 billion in 2026.

Major growth drivers include rising elderly AML incidence, expansion of precision oncology, increasing adoption of targeted therapies, growing relapse treatment demand, and wider genomic testing integration.

Targeted therapies are gaining adoption because they provide more personalized treatment with lower toxicity compared to traditional intensive chemotherapy, especially in elderly or frail patients.

High treatment costs, expensive genomic testing, therapy durability concerns, and stem cell transplantation dependency remain key barriers.

Asia Pacific is witnessing rapid growth because of improving oncology infrastructure, rising cancer awareness, expanding genomic testing, and increasing healthcare investments.

Need data specifically for your business?Request Custom Research →

Trusted by the world's leading organizations

Weber Shandwick
veolia
Tri
tls
TeamViewer
GE Healthcare
Intel
Proctor and Gamble
ABB
Elkem
Defense Logistics Agency
Amazon